tbuckley/cabot-search huggingface dataset:
CMET-20. ANALYSIS OF NANO-SIZED PARTICLE IN HUMAN CEREBROSPINAL FLUID: A MEASUREMENT OF EXTRACELLULAR VESICLE CONCENTRATION CHANGE WITH MIR-21 EXPRESSION AFTER CHEMOTHERAPY FOR LEPTOMENINGEAL CARCINOMATOSIS
Authors: Kyue-Yim Lee, Wei-wei Lin, Ho-Shin Gwak, Jong Heon Kim, Byong Chul Yoo, Tae-Hoon Kim, Jong Bae Park, Hyeon Jin Park, Ho-Jin Kim, Ji Woong Kwon, Sang Hoon Shin, Heon Yoo
Journal: Neuro-Oncology (2019)

Abstract PURPOSE For comparing the distribution and concentrations of nano-sized micro-molecules in cerebrospinal fluid (CSF) according to different central nervous system (CNS) disease METHODS We have collected CSF of 447 patients from 6 different groups (systemic cancer, healthy control, leptomeningeal carcinomatosis (LMC), brain metastasis, other brain tumor, and other CNS disease). After cell down by centrifugation, proportion of nano-sized particle is measured by Nano-sizer and absolute number of extracellular vesicle (EV, 100–1,000 nm) is counted by Nano-sight. We verified exosomes in our CSF samples by exosome purification and Western blot. RESULTS In Nano-sizer, two peaks appeared at mean 10.5 nm and 174 nm. The small peak is presumed to be nucleic acid and protein as we could decrease or eliminate the peak by nucleic acid elimination kit or proteinase. The proportion of large peak, presumed to represent EVs, is significantly higher in LMC group than all other groups (mean 64% vs. 44%, p &lt; 0.001). And also, the count of EV is significantly higher in patients with LMC (7.15 x 108 vs. 3.46 x 108, p &lt; 0.001). Furthermore, we evaluated paired EV concentration of pre- and post-treatment of intra-CSF chemotherapy in non-small lung cancer patients with LMC (n=33). Overall survival of patients was significantly prolonged in patients with increased EV count compared to those of decreased or ‘no-change’ (&lt; 20%) (442 vs. 165 days, p &lt; 0.001). The expression level of onco-microRNA (miR-21) is decreased significantly after the treatment in this favorable prognostic group (p &lt; 0.01). CONCLUSION We expect to obtain appropriate variables representing cancer cell activity in the CSF samples by observing this nano-sized molecule proportion and EV concentration with onco-miR expression. KEY WORDS: cerebrospinal fluid, exosome, extracellular vesicle, microRNA, leptomeningeal carcinomatosis
Indoor Plumbing Drains Are Important Sources for Invasive Fusariosis in Patients with Hematological Disorders: Culture-Based and Metagenomic Analysis
Authors: Yutaro Hino, Muraosa Yasunori, Akira Watanabe, Kyoko Yarita, Maki Yahiro, Emiko Sakaida, Koutaro Yokote, Katsuhiko Kamei
Journal: Blood (2019)
Identification of a Novel Long Intergenic Noncoding RNA - Linc00936, with Significant Impact on Multiple Myeloma Cell Growth Via mTOR Pathway Inhibition
Authors: Annamaria Gulla, Mehmet Kemal Samur, Mariateresa Fulciniti, Masood A Shammas, Teru Hideshima, Pierosandro Tagliaferri, Giovanni Parmigiani, Pierfrancesco Tassone, Kenneth C Anderson, Nikhil C. Munshi
Journal: Blood (2015)
Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas
Authors: Julia Cluceru, Sarah J Nelson, Qiuting Wen, Joanna J Phillips, Anny Shai, Annette M Molinaro, Paula Alcaide-Leon, Marram P Olson, Devika Nair, Marisa LaFontaine, Pranathi Chunduru, Javier E Villanueva-Meyer, Soonmee Cha, Susan M Chang, Mitchel S Berger, Janine M Lupo
Journal: Neuro-Oncology (2020)

Differentiating treatment-induced injury from recurrent high-grade glioma is an ongoing challenge in neuro-oncology, in part due to lesion heterogeneity. This study aimed to determine whether different MR features were relevant for distinguishing recurrent tumor from the effects of treatment in contrast-enhancing lesions (CEL) and non-enhancing lesions (NEL).This prospective study analyzed 291 tissue samples (222 recurrent tumor, 69 treatment-effect) with known coordinates on imaging from 139 patients who underwent preoperative 3T MRI and surgery for a suspected recurrence. 8 MR parameter values were tested from perfusion-weighted, diffusion-weighted, and MR spectroscopic imaging at each tissue sample location for association with histopathological outcome using generalized estimating equation models for CEL and NEL tissue samples. Individual cutoff values were evaluated using receiver operating characteristic curve analysis with 5-fold cross-validation.In tissue samples obtained from CEL, elevated relative cerebral blood volume (rCBV) was associated with the presence of recurrent tumor pathology (P < 0.03), while increases in normalized choline (nCho) and choline-to-NAA index (CNI) were associated with the presence of recurrent tumor pathology in NEL tissue samples (P < 0.008). A mean CNI cutoff value of 2.7 had the highest performance, resulting in mean sensitivity and specificity of 0.61 and 0.81 for distinguishing treatment-effect from recurrent tumor within the NEL.Although our results support prior work that underscores the utility of rCBV in distinguishing the effects of treatment from recurrent tumor within the contrast enhancing lesion, we found that metabolic parameters may be better at differentiating recurrent tumor from treatment-related changes in the NEL of high-grade gliomas.
A GPI-Anchored Protein, CD109, Protects Hematopoietic Progenitor Cells from Erythroid Differentiation Induced By TGF-β
Authors: Tanabe Mikoto, Nguyen Hoang Maianh, Kohei Hosokawa, Noriharu Nakagawa, Luis Espinoza, Hirohito Yamazaki, Shinji Nakao
Journal: Blood (2019)
Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
Authors: Jennifer Woyach, Deborah M. Stephens, Ian W. Flinn, Seema A. Bhat, Ronald E. Savage, Feng Chai, Sudharshan Eathiraj, Lindsey Granlund, Lyndsey A. Szuszkiewicz, Brian Schwartz, John C. Byrd
Journal: Blood (2019)
Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)
Authors: Yoshiko Azuma, Tomoki Ito, Muneo Inaba, Kai Imai, Masaaki Hotta, Atsushi Satake, Shosaku Nomura
Journal: Blood (2019)
STERILITY OF MARKET COTTON
Authors: John H. Silliker
Journal: JAMA (1952)

The consumer's guarantee of sterility in products labeled "sterile" lies chiefly with the producer. In the case of "sterile" market cotton,<sup>1</sup>the control program of the Food and Drug Administration, in the Los Angeles area at least, consists of taking random samples at periodic intervals. These are sent to the Federal Drug Administration in Washington, D. C., for sterility testing. Results of these investigations are not available. In view of this, it was decided to make a survey of "sterile" market cotton to determine whether the present control program is adequate to insure sterility in all packages of cotton. <h3>EXPERIMENTAL DATA</h3><h3>Procurement.—</h3> Samples of "sterile" market cotton were purchased from retail stores in various parts of the city of Los Angeles. Generally a single 4-oz. roll of a nationally prominent brand was purchased from each retailer. At the time of purchase, no mention was made of the survey being
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)
Authors: Adrian Wagg, David Staskin, Eli Engel, Sender Herschorn, Rita M. Kristy, Carol R. Schermer
Journal: European Urology (2019)

The majority of patients with overactive bladder (OAB) are aged >65 yr. There has been no prospectively designed study assessing treatment efficacy with the β3-adrenoreceptor agonist, mirabegron, specifically in this age group. A phase IV study comparing flexibly dosed mirabegron versus placebo in elderly patients with OAB and urgency incontinence. Community-dwelling patients aged ≥65 yr with OAB for ≥3 mo. Following a 2-wk placebo run in, patients with one or more incontinence episodes, three or more urgency episodes, and an average of eight or more micturitions/24 h were randomised 1:1 to double-blind 25 mg/d mirabegron or matched placebo, for 12 wk. After week 4 or 8, the dose could be increased to 50 mg/d mirabegron/matched placebo based on patient and investigator discretion. Coprimary endpoints: change from baseline to end of treatment (EOT) in the mean numbers of micturitions/24 h and incontinence episodes/24 h. Secondary endpoints: change from baseline to EOT in the mean volume voided/micturition, mean number of urgency episodes/24 h, and mean number of urgency incontinence episodes/24 h. Analysis of covariance (ANCOVA) was used for the mean number of micturitions/24 h, mean volume voided/micturition, and mean number of urgency episodes/24 h. Stratified rank ANCOVA was used for the mean numbers of incontinence episodes/24 h and urgency incontinence episodes/24 h. Statistically significant improvements were observed for mirabegron versus placebo in change from baseline to EOT in the mean number of micturitions/24 h, mean number of incontinence episodes/24 h, mean volume voided/micturition, mean number of urgency episodes/24 h, and mean number of urgency incontinence episodes/24 h. Safety and tolerability were consistent with the known mirabegron safety profile. Mirabegron efficacy, safety, and tolerability over 12 wk were confirmed in patients aged ≥65 yr with OAB and incontinence. We examined the effect of mirabegron compared with placebo in people aged 65 yr or older with overactive bladder and incontinence. Mirabegron improved the symptoms of overactive bladder compared with placebo. Side effects were similar to those already known for mirabegron.
Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients
Authors: Abby Statler, Brian P. Hobbs, Tomas Radivoyevitch, Caitlin Siebenaller, Sudipto Mukherjee, Anjali S. Advani, Aaron T. Gerds, Aziz Nazha, Bhumika J. Patel, Hetty E. Carraway, Mikkael A. Sekeres
Journal: Blood (2019)
Associations of screen time, sedentary time and physical activity with sleep in under 5s: A systematic review and meta-analysis
Authors: Xanne Janssen, Anne Martin, Adrienne R. Hughes, Catherine M. Hill, Grigorios Kotronoulas, Kathryn R. Hesketh
Journal: Sleep Medicine Reviews (2019)

Sleep is crucial to children's health and development. Reduced physical activity and increased screen time adversely impact older children's sleep, but little is known about these associations in children under 5 y. This systematic review examined the association between screen time/movement behaviors (sedentary behavior, physical activity) and sleep outcomes in infants (0–1 y); toddlers (1–2 y); and preschoolers (3–4 y). Evidence was selected according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and synthesized using vote counting based on the direction of association. Quality assessment and a Grading of Recommendations, Assessment, Development and Evaluation was performed, stratified according to child age, exposure and outcome measure. Thirty-one papers were included. Results indicate that screen time is associated with poorer sleep outcomes in infants, toddlers and preschoolers. Meta-analysis confirmed these unfavorable associations in infants and toddlers but not preschoolers. For movement behaviors results were mixed, though physical activity and outdoor play in particular were favorably associated with most sleep outcomes in toddlers and preschoolers. Overall, quality of evidence was very low, with strongest evidence for daily/evening screen time use in toddlers and preschoolers. Although high-quality experimental evidence is required, our findings should prompt parents, clinicians and educators to encourage sleep-promoting behaviors (e.g., less evening screen time) in the under 5s.
A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia
Authors: Justin M. Watts, Terrence J Bradley, Amber Thomassen, Andrew M. Brunner, Mark D. Minden, Nikolaos Papadantonakis, Sameem Abedin, Amanda J Baines, Olena Barbash, Shelby Gorman, Brandon E Kremer, Gautam M. Borthakur
Journal: Blood (2019)
Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance
Authors: Rafael Renatino-Canevarolo, Praneeth Reddy Sudalagunta, Maria D Coelho Siqueira Silva, Mark B. Meads, Alexandre Tungesvik, Gabriel De Avila, Alugubelli Raghunandan Reddy, Minerva Nong, Jamie Teer, Eric A. Welsh, Tint Lwin, Amit Kulkarni, Hongyue Dai, William S. Dalton, Kenneth H. Shain, Ariosto Siqueira Silva
Journal: Blood (2019)
Abstract 17241: The Bone Marrow-Mediated Adipokine Resistin Like Alpha Impairs Cardiac Recovery Through Apoptosis and Fibrosis After Myocardial Infarction
Authors: Yong Sook Kim, Wan Seok Kang, Youngkeun Ahn
Journal: Circulation (2017)

Introduction: Resistin like alpha (Retnla) is characterized as an adipokine and known to modulate cholesterol homeostasis, and the involvement of Fizz1 in cardiac pathology is unknown. Hypothesis: ...
Spinal Epidural Abscess
Authors: A. Hulme, N. M. Dott
Journal: BMJ (1954)

Infection of the spinal epidural fatty areolar tissue by pyogenic organisms is generally regarded as a rare condition.Although a well-recognized clinical entity, it has received little attention in British medical literature.In contrast, that of the United States contains a number of excellent reviews of the subject, notably by Dandy (1926), Gasul and Jaffe (1935), Browder and Meyers (1937, 1941), Rankin and Flothow (1946), Huesner (1948).In 1926 Dandy found only 25 cases in the literature.Rankin and Flothow were able to review 225 cases in 1946, and two years later Huesner reported a further 20 cases.This communication is based upon a series of 25 cases of spinal epiduial suppuration, 19 of which have been treated in the department of surgical neurology, Edin- burgh Royal Infirmary, between 1933 and 1952, and 6 in.theBristol Neurosurgical centre during the past four years.In Bristol during the same period there were 21 cases of spinal tumour, 10 of which were meningioma or neurinoma.This is too small a series from which to draw deductions, but it does at any rate suggest that spinal epidural abscess is proportionally a not infrequent cause of interference with spinal cord function.
Therapeutic Plasma Exchange (PLEX) in Thrombotic Microangiopathy (TMA): Experiences of an Inner-City Hospital over a Decade
Authors: Aakash Putta, Hafeez Shaka, Shristi Upadhyay Banskota, Sunny R K Singh, Sindhu Malapati, Muhammad Zain Farooq, Kumar Kunnal Batra
Journal: Blood (2019)
艾滋病（二）：抗逆转录病毒药物
Authors: IanVDWeller, IGWilliams
Journal: BMJ (2002)

近几年由于抗逆转录病毒药物的应用 ,艾滋病毒 (ＨＩＶ)感染和艾滋病 (ＡＩＤＳ)的临床疗效有明显改进。 1996年以来发达国家ＡＩＤＳ的新发病例和死亡率急速下降。发表的数据表明 ,1990年底ＣＤ4计数<10 0× 10 6 Ｌ的ＡＩＤＳ病人死亡率下降了约 2 3,每10 0名病人中低于 8人。虽然还不能确定常规抗逆转录病毒治疗的长期疗效 ,但其生物学原理以及持续临床效果已被证实。抗逆转录病毒治疗可持续抑制病毒复制 ,使部分免疫系统重建 ,从而降低疾病的进一步发展及死亡率。ＨＩＶ可以潜伏在静止的Ｔ淋巴细胞和其他长期存活的细胞群内 ,因此单一的抗逆转录病毒治疗似乎不可能清除病毒 ,长期用药
Plaque psoriasis in patients with palmoplantar pustulosis
Authors: Y.M.F. Andersen, M. Augustin, J. Petersen, K. Hagenström, L. Mallbris, R. Burge, A. Egeberg
Journal: British Journal of Dermatology (2019)

This study from the USA, Denmark and Germany looked at how often plaque psoriasis and palmoplantar pustulosis (PPP) occur together. Plaque psoriasis is the commonest form of psoriasis. PPP is a condition where pus‐filled spots are seen on the palms and soles, often on skin that is red and scaly like psoriasis. It is not known how PPP is related to psoriasis, if at all. From insurance records in the USA and Germany, and from the Danish National Patient Register, the researchers found approximately 4000 patients diagnosed with PPP. Many of their findings varied strikingly from country to country, as noted in the commentary for this study. For instance, the prevalence of PPP ranged from 0.005% in Denmark to 0.08% in Germany. The presence of plaque psoriasis in PPP patients varied from 14.2% in the Danish patients to 36.4% in Germany and 61.3% in the USA. As regards treatment, patients with PPP and plaque psoriasis together were more likely to have been prescribed strong steroid creams, ointments or gels, especially in the USA and Denmark. More patients with both conditions together were treated with acitretin, methotrexate and biologics in the USA and Denmark, and the differences for treatment with biologics ranged widely: 18.4% of USA patients compared with 8.5% in Denmark and 2.5% in Germany. In comparison with patients with PPP alone, patients who had PPP and plaque psoriasis together were more likely to have joint disease related to psoriasis, and this was roughly the same in all three countries.
The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support
Authors: Amit P. Amin, John A. Spertus, Jeptha P. Curtis, Nihar Desai, Frederick A. Masoudi, Richard G. Bach, Christian McNeely, Firas Al-Badarin, John A. House, Hemant Kulkarni, Sunil V. Rao
Journal: Circulation (2019)

Background: Impella was approved for mechanical circulatory support (MCS) in 2008, but large-scale, real-world data on its use are lacking. Our objective was to describe trends and variations in Impella use, clinical outcomes, and costs across US hospitals in patients undergoing percutaneous coronary intervention (PCI) treated with MCS (Impella or intra-aortic balloon pump). Methods: From the Premier Healthcare Database, we analyzed 48 306 patients undergoing PCI with MCS at 432 hospitals between January 2004 and December 2016. Association analyses were performed at 3 levels: time period, hospital, and patient. Hierarchical models with propensity adjustment were used for association analyses. We examined trends and variations in the proportion of Impella use, and associated clinical outcomes (in-hospital mortality, bleeding requiring transfusion, acute kidney injury, stroke, length of stay, and hospital costs). Results: Among patients undergoing PCI treated with MCS, 4782 (9.9%) received Impella; its use increased over time, reaching 31.9% of MCS in 2016. There was wide variation in Impella use across hospitals (&gt;5-fold variation). Specifically, among patients receiving Impella, there was a wide variation in outcomes of bleeding (&gt;2.5-fold variation), and death, acute kidney injury, and stroke (all ≈1.5-fold variation). Adverse outcomes and costs were higher in the Impella era (years 2008–2016) versus the pre-Impella era (years 2004–2007). Hospitals with higher Impella use had higher rates of adverse outcomes and costs. After adjustment for the propensity score, and accounting for clustering of patients by hospitals, Impella use was associated with death: odds ratio, 1.24 (95% CI, 1.13–1.36); bleeding: odds ratio, 1.10 (95% CI, 1.00–1.21); and stroke: odds ratio, 1.34 (95% CI, 1.18–1.53), although a similar, nonsignificant result was observed for acute kidney injury: odds ratio, 1.08 (95% CI, 1.00–1.17). Conclusions: Impella use is rapidly increasing among patients undergoing PCI treated with MCS, with marked variability in its use and associated outcomes. Although unmeasured confounding cannot be ruled out, when analyzed by time periods, or at the hospital level or the patient level, Impella use was associated with higher rates of adverse events and costs. More data are needed to define the appropriate role of MCS in patients undergoing PCI.
Helen Salisbury: The ethics of medical memoirs
Authors: Helen Salisbury
Journal: BMJ (2019)

One of the things I like most about my job is the opportunity to learn about patients’ lives: the events and incidents that have led to the current consultation, and the people involved. My timekeeping sometimes suffers because of my curiosity. When I hear surprising and interesting stories, there can be a natural urge to share them. When bad things happen, I may need to talk to my colleagues or offload on my family. But, if I do this, what is permissible?

The rules about confidentiality, when there is a risk that …
SCIDOT-44. CREATING CAUSAL CAPABILITIES IN FUNCTIONAL BRAIN MAPPING USING A CED APPROACH
Authors: Walter Block, Rasmus Birns, Miles Olsen, Samuel Hurley, Ethan Brodsky, Abigail Rajala, Caitlynn Filla, Alan McMillan, Andrew Alexander, Rick Jenison, Luis Populin
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION The spatial and temporal resolution limits of functional MRI (fMRI) brain mapping provide primarily correlative information on brain connectivity. Determining how one region causally modulates and mediates activity in other regions remains difficult with fMRI. We demonstrate a simple means to add causality in resting state functional connectivity MRI (rs-fcMRI) using techniques developed first for convection-enhanced delivery (CED) of therapeutics. Here we use CED to guide and monitor pharmacologic alteration of a local brain region in anaesthetized Rhesus monkeys while monitoring rs-fcMRI signal changes. METHODS Pre-surgical MRI was used to determine skull locations for craniotomies for installation of NavigusTMbrain ports in two untrained monkeys slated for euthanasia. The ports were aligned in real–time to provide trajectories aimed at the central nucleus of the amygdala (CeA). Fused silica catheters were then inserted into the CeA where 24 mg of muscimol (inhibitory agent) was infused in 24 ml of buffered solution under pressure over 12 minutes, first on the right side and then on the left side. rs-fcMRI studies were done for 45 minutes before and after the unilateral infusion and then after the bilateral infusion. RESULTS Catheters were successfully aligned and inserted into the CeA targets with sub-mm accuracy. T2-weighted imaging detected the enhanced T2 from the infusion’s buffer. Pre-infusion rs-fcMRI provides results consistent with prior studies, which have shown that the CeA is most strongly connected to the contralateral CeA. This connectivity was significantly reduced following both unilateral and bilateral injections of muscimol into the CeA, demonstrating the effectiveness of the muscimol infusions. Conditional Grainger Causality (CGC) analysis shows unexpected new connectivity after the unilateral infusion. Upon the bilateral infusion, global effective connectivity in the region is reduced. CONCLUSION Expected and unexpected changes in resting state functional connectivity resulted from unilateral and bilateral infusions of inhibitory agents.
Real World Outcomes in Latin-American Patients with Multiple Myeloma Under 40 Years Old
Authors: Humberto Martínez-Cordero, Camila Peña, Natalia Paola Schutz, Virginia Bove, Fiorella Villano, Rocío Osorio, Mauricio Chandia, Cecilia Beltran, Javier Schulz, Daniela Cardemil, Carolina Contreras, Carmen Gloria Vergara, Javiera Donoso, Marcela Espinoza, Gabriel La Rocca, Hernán López-Vidal, Pilar León, Macarena Alejandra Roa Salinas, Christine Rojas, Pablo Soto, Sandra Aranda, Vivianne Torres, Paola Ochoa, Patricio Duarte, Guillermina Remaggi, Sebastian Yantorno, Ariel Corzo, Soledad Zabaljauregui, Claudia Shanley, Sergio Lopresti, Sergio Orlando, Veronica Verri, Luis Darío Quiroga, Juan Jose Garcia, Vanesa Fernandez, Dorotea Fantl, Jhoanna Ramirez, Alicia Molina, Pilar Papilco, Alex Mite, Ines Reyes, Brenner Sabando, Francisca M. Ramirez Aspiazu, Claudia Lucia Sossa, Virginia Abello, Henry Idrobo, Domingo Saavedra, Guillermo Quintero, Lina Gaviria, Rigoberto Gomez, Monica Osuna Pérez, Alicia Henao-Uribe, Luz del Carmen Tarín Arzaga, Omar Cantú-Martínez, David Gomez-Almaguer, Yarely Itzayana García-Navarrete, Antonio Cruz-Mora, Yahveth Cantero-Fortiz, Guillermo J. Ruiz-Arguelles, Eloisa Riva
Journal: Blood (2019)
A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Lymphoma
Authors: Anas Younes, Connie Lee Batlevi, Jonathon B. Cohen, Sven de Vos, Daniel J. Landsburg, Zaw Win Myint, Krish Patel, Tycel J. Phillips, Sonali M. Smith, Jason R. Westin, Anna W Ma, Dena Grayson, Reinhard von Roemeling, Stefan K. Barta
Journal: Blood (2019)